Search Results - "Burmester, Gerd"

Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2026, Vol. 13 Issue 1, p293-297. 5p.

Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges.

Authors: Joshi, Mrudula Darooka, Naitica Saha, Sreoshy et al.

Source: International Journal of Rheumatic Diseases. May2024, Vol. 27 Issue 5, p1-9. 9p.

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p221-222. 2p.

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Authors: Burmester, Gerd R. Stigler, Jayne Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p737-753. 17p.

Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors.

Authors: Mandecka, Anna Perlak, Karolina Bajek, Wiktoria et al.

Source: CTS: Clinical & Translational Science. Mar2026, Vol. 19 Issue 3, p1-8. 8p.

Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA).

Authors: Pongratz, Georg Alten, Rieke Witte, Torsten et al.

Source: Rheumatology & Therapy. Apr2026, Vol. 13 Issue 2, p435-449. 15p.

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.

Authors: Burmester, Gerd R. Winthrop, Kevin Blanco, Ricardo et al.

Source: Rheumatology & Therapy. Apr2022, Vol. 9 Issue 2, p521-539. 19p.

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.

Authors: Burmester, Gerd Trefler, Jakub Racewicz, Artur et al.

Source: Clinical Drug Investigation. Aug2025, Vol. 45 Issue 8, p551-563.

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Dec2023, Vol. 10 Issue 6, p1575-1595. 21p.

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Oct2023, Vol. 10 Issue 5, p1255-1276. 22p.

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.

Authors: Combe, Bernard G. Tanaka, Yoshiya Buch, Maya H. et al.

Source: Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p71-72. 2p.

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.

Authors: Krüger, Klaus Burmester, Gerd Rüdiger Wassenberg, Siegfried et al.

Source: Rheumatology & Therapy. Jun2020, Vol. 7 Issue 2, p371-382. 12p.

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p73-93. 21p.

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.

Authors: Conaghan, Philip Cohen, Stanley Burmester, Gerd et al.

Source: Rheumatology & Therapy. Feb2022, Vol. 9 Issue 1, p191-206. 16p.

A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.

Authors: Burmester, Gerd Chien, David Chow, Vincent et al.

Source: Clinical Pharmacology in Drug Development. Nov/Dec2020, Vol. 9 Issue 8, p1003-1014. 12p.

Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).

Authors: Koehm, Michaela Foldenauer, Ann C. Rossmanith, Tanja et al.

Source: Journal of Clinical Medicine. Dec2022, Vol. 11 Issue 24, p7316. 13p.

Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.

Authors: Charles-Schoeman, Christina Giles, Jon T. Lane, Nancy E. et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p157-175. 19p.

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis.

Authors: Curtis, Jeffrey R. Emery, Paul Downie, Bryan et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p177-189. 13p.

Tofacitinib for rheumatoid arthritis - Authors' reply.

Authors: Burmester, Gerd R Benda, Birgitta Gruben, David et al.

Source: Lancet. 5/25/2013, Vol. 381 Issue 9880, p1812-1813. 2p.

URL: 87807033

PUBLICATIONS OF THE WEEK.

Source: Bookseller; 7/4/2003, Issue 5084, p35, 18p